Download - Figure S1
Transcript
Figure S1
A
B
0 nM 1nM 5nM 25 nM 125 nM 625 nM 0
0.2
0.4
0.6
0.8
1
1.2
MCF7
INK 128
RAD001
GDG00941
Drug Concentration
Via
bil
ity
0 nM 1nM 5nM 25 nM 125 nM 625 nM 0
0.2
0.4
0.6
0.8
1
1.2
MCF7/HER2-18
INK 128
RAD001
GDG00941
Drug Concentration
Via
bil
ity
0 nM 1nM 5nM 25 nM 125 nM 625 nM 0
0.2
0.4
0.6
0.8
1
1.2
SKBR3
INK 128
RAD001
GDG00941
Drug Concentration
Via
bil
ity
C
Figure S2
MLN
0128
0 nM
5 nM
25 n
M
125
nM
0 nM
5 nM
25 n
M
125
nM
0 nM
5 nM
25 n
M
125
nM
SAHA 0 nM 625 nM 3125 nM
0
0.2
0.4
0.6
0.8
1
1.2
MCF7V
iabi
lity
Antagonism Synergism
Additivity
SAHA(nM)
625 625 625 3125 3125 3125
MLN0128(nM)
5 25 125 5 25 125
CI 0.728 0.394 0.368 0.412 0.206 0.151
A
B
Figure S3
DMSO
MLN0128
TSA
MLN0128/TSA
Bright-field Annexin V PI merge
no tr
eatm
ent
pAKT S473
AKT
0 1000
0 25
TSA (nM)
INK128 (nM)
50
0 25 0 25
pAKT T308
Figure S4
SKBR3
